GEHC vs DXCM vs EW
161 measures in 16 categories, one definition each, computed from filings and market data.
GEHC26.1
GE HealthCare Technologies Inc.
Healthcare · Medical - Devices
$69.57 −1.11%$31.4B mkt cap
Score DNA
EW64.7
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$86.60 −1.70%$49.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
GEHC DXCM EW · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Insider open-market buys, 180d | 8 | 0 | 0 |
| Insider $ bought, 180d | $6.42M | — | — |
| Congress purchases, 180d | 6 | 1 | 2 |
| Last Congress purchase | 2026-09-11 | 2026-05-01 | 2026-05-01 |
| 13F net change in holders | −37 | +14 | +46 |
| ETFs adding shares, 30d | 1,125 | 1,144 | 1,345 |
| ETFs trimming, 30d | 927 | 1,098 | 1,066 |
| Net ETF funds, 30d | +198 | +46 | +279 |
Valuation
16 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| P/E (TTM) | 19.7x
26th
|
32.5x
63rd
|
49.7x
89th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 3.23
93rd
|
0.71
27th
|
— |
| Price / sales | 1.6x
17th
|
6.5x
78th
|
7.7x
82nd
|
| Price / book | 2.9x
43rd
|
12.4x
91st
|
4.7x
61st
|
| Price / tangible book | — | 10.6x
71st
|
7.2x
54th
|
| Price / free cash flow | 35.1x
72nd
|
23.1x
42nd
|
34.8x
69th
|
| Price / operating cash flow | 22.2x
58th
|
18.6x
42nd
|
29.0x
70th
|
| Enterprise value | $39.4B
92nd
|
$31.9B
90th
|
$46.4B
93rd
|
| EV / sales | 1.9x
18th
|
6.4x
78th
|
7.1x
82nd
|
| EV / EBITDA | 11.3x
32nd
|
20.5x
61st
|
29.3x
76th
|
| EV / EBIT | 16.0x
21st
|
24.6x
48th
|
32.7x
73rd
|
| EV / free cash flow | 44.0x
72nd
|
22.7x
33rd
|
32.3x
56th
|
| Earnings yield | 5.1%
88th
|
3.1%
72nd
|
2.0%
60th
|
| FCF yield | 2.8%
57th
|
4.3%
75th
|
2.9%
58th
|
| Operating cash flow yield | 4.5%
58th
|
5.4%
70th
|
3.4%
50th
|
| Graham number (per share) | $43.67
52nd
|
$19.60
22nd
|
$26.83
30th
|
Profitability (TTM)
12 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Gross margin | 42.9%
13th
|
62.5%
47th
|
78.0%
87th
|
| EBITDA margin | 17.2%
68th
|
31.4%
95th
|
24.3%
83rd
|
| Operating margin | 12.7%
72nd
|
22.9%
95th
|
28.1%
97th
|
| EBIT margin | 12.2%
70th
|
26.1%
95th
|
21.8%
92nd
|
| Net margin | 7.9%
65th
|
20.1%
95th
|
15.4%
90th
|
| NOPAT margin | 9.9%
68th
|
17.9%
90th
|
19.4%
92nd
|
| FCF margin | 4.4%
53rd
|
28.3%
98th
|
22.0%
93rd
|
| Operating cash flow margin | 7.0%
48th
|
35.2%
100th
|
26.4%
95th
|
| R&D / revenue | 6.5%
32nd
|
12.2%
64th
|
16.7%
73rd
|
| SG&A / revenue | 21.3%
8th
|
27.4%
13th
|
33.8%
25th
|
| Stock comp / revenue | 0.6%
10th
|
3.3%
48th
|
2.6%
47th
|
| Effective tax rate | 21.8%
78th
|
21.9%
79th
|
31.0%
91st
|
Returns on capital
11 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| ROE (on average equity) | 15.4%
81st
|
38.5%
100th
|
9.5%
66th
|
| ROA | 4.4%
68th
|
14.5%
97th
|
7.3%
77th
|
| ROIC | 10.6%
69th
|
42.9%
97th
|
17.9%
85th
|
| ROCE | 8.5%
68th
|
31.6%
98th
|
11.5%
80th
|
| Return on tangible assets | 6.8%
67th
|
18.8%
98th
|
10.4%
83rd
|
| Cash ROIC (OCF / invested capital) | 7.5%
54th
|
84.4%
100th
|
24.3%
85th
|
| Gross profitability (GP / assets) | 23.3%
18th
|
48.1%
63rd
|
36.6%
52nd
|
| ROIC, 3-yr average | 9.3%
76th
|
26.2%
94th
|
28.3%
96th
|
| ROIC, 5-yr average | — | 23.1%
94th
|
45.2%
96th
|
| ROE, 5-yr average | — | 22.7%
94th
|
23.0%
96th
|
| Incremental ROIC | 50.4%
63rd
|
-39.1%
25th
|
— |
Growth
17 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Revenue growth (TTM YoY) | 1.4%
12th
|
15.5%
64th
|
14.6%
59th
|
| Revenue growth (QoQ) | 3.2%
22nd
|
9.8%
60th
|
5.6%
40th
|
| Revenue CAGR, 3 yr | 11.9%
53rd
|
15.8%
64th
|
6.3%
30th
|
| Revenue CAGR, 5 yr | — | 18.0%
69th
|
5.7%
23rd
|
| Gross profit CAGR, 3 yr | 14.6%
62nd
|
14.9%
65th
|
6.4%
25th
|
| Operating income CAGR, 3 yr | 10.5%
44th
|
36.5%
76th
|
4.4%
28th
|
| Net income growth (TTM YoY) | -29.0%
33rd
|
74.9%
88th
|
-75.8%
4th
|
| Net income CAGR, 3 yr | 5.8%
35th
|
40.9%
80th
|
-10.2%
15th
|
| EPS growth (TTM YoY) | -28.3%
33rd
|
82.2%
88th
|
-75.3%
4th
|
| EPS CAGR, 3 yr | 6.1%
30th
|
45.5%
80th
|
-8.6%
10th
|
| EPS CAGR, 5 yr | — | 15.5%
70th
|
-5.6%
15th
|
| FCF growth (TTM YoY) | -42.8%
3rd
|
146.1%
87th
|
135.8%
83rd
|
| FCF CAGR, 3 yr | -8.1%
12th
|
44.5%
62nd
|
28.1%
46th
|
| Operating cash flow CAGR, 3 yr | -0.6%
16th
|
31.4%
68th
|
22.3%
61st
|
| Book value CAGR, 3 yr | 16.0%
78th
|
11.2%
65th
|
20.7%
86th
|
| Dividend CAGR, 3 yr | 3.0%
62nd
|
— | — |
| Sustainable growth rate | 14.8%
70th
|
38.5%
100th
|
9.5%
41st
|
Margin history & stability
7 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Gross margin, 3-yr average | 41.8%
13th
|
61.3%
43rd
|
78.5%
89th
|
| Operating margin, 3-yr average | 13.0%
74th
|
18.7%
92nd
|
27.2%
98th
|
| Net margin, 3-yr average | 9.1%
72nd
|
16.8%
92nd
|
38.8%
100th
|
| FCF margin, 3-yr average | 6.8%
57th
|
19.5%
96th
|
14.3%
81st
|
| Revenue stability (0-1) | 0.70
19th
|
0.99
96th
|
0.77
28th
|
| Earnings stability (0-1) | 0.22
40th
|
0.54
70th
|
0.07
13th
|
| Margin stability (0-1) | 0.97
72nd
|
0.94
26th
|
0.98
94th
|
Liquidity (latest quarter)
7 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Cash & short-term investments | $2.1B
93rd
|
$1.9B
92nd
|
$4.3B
97th
|
| Net cash (− = net debt) | −$8.0B
7th
|
$548.6M
97th
|
$3.5B
100th
|
| Working capital | $167.0M
27th
|
$1.7B
85th
|
$5.3B
95th
|
| Current ratio | 1.02
3rd
|
1.73
20th
|
4.52
68th
|
| Quick ratio | 0.72
5th
|
1.43
28th
|
3.77
70th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.25
20th
|
0.83
47th
|
2.82
72nd
|
| Defensive interval (days) | 357 days
58th
|
600 days
85th
|
585 days
83rd
|
Leverage & solvency (latest quarter)
13 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Total debt | $10.1B
93rd
|
$1.4B
82nd
|
$704.4M
58th
|
| Debt / equity | 0.92
79th
|
0.53
49th
|
0.07
21st
|
| Net debt / equity | 0.73
75th
|
−0.21
37th
|
−0.33
26th
|
| Debt / assets | 27.1%
48th
|
21.7%
43rd
|
5.1%
18th
|
| Debt / capital | 47.9%
79th
|
34.8%
49th
|
6.2%
21st
|
| Debt / EBITDA | 2.90
55th
|
0.90
18th
|
0.45
16th
|
| Net debt / EBITDA | 2.30
55th
|
−0.35
32nd
|
−2.24
8th
|
| Interest coverage (EBIT / interest) | 5.7x
73rd
|
86.3x
92nd
|
— |
| Cash interest coverage | 3.2x
50th
|
116.6x
92nd
|
— |
| Debt payback (years of OCF) | 7.1 yrs
70th
|
0.8 yrs
21st
|
0.4 yrs
14th
|
| Liabilities / assets | 70.5%
85th
|
59.4%
70th
|
22.7%
17th
|
| IS credit model rating | BB+ | AAA | AA+ |
| Implied credit spread (bps) | 400
63rd
|
50
0th
|
65
8th
|
Efficiency
11 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Asset turnover | 0.56
38th
|
0.72
62nd
|
0.48
22nd
|
| Fixed asset turnover | 6.43
67th
|
2.98
12th
|
3.35
16th
|
| Inventory turnover | 4.9
86th
|
2.9
79th
|
1.3
19th
|
| Receivables turnover | 5.0
22nd
|
3.8
8th
|
8.9
92nd
|
| Days sales outstanding | 73 days
78th
|
96 days
92nd
|
41 days
8th
|
| Days inventory outstanding | 75 days
14th
|
127 days
21st
|
289 days
81st
|
| Days payables outstanding | 98 days
83rd
|
88 days
78th
|
47 days
40th
|
| Cash conversion cycle (days) | 50 days
10th
|
135 days
30th
|
283 days
85th
|
| Capex / revenue | 2.6%
33rd
|
6.9%
90th
|
4.4%
64th
|
| Capex / depreciation | 0.52
36th
|
1.30
74th
|
1.73
79th
|
| Operating expense ratio | 27.2%
7th
|
39.1%
10th
|
47.7%
29th
|
Cash flow & earnings quality
7 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Operating cash flow / net income | 0.89
4th
|
1.75
63rd
|
1.71
56th
|
| FCF / net income | 0.56
7th
|
1.41
59th
|
1.43
63rd
|
| FCF / operating cash flow | 63.2%
48th
|
80.3%
69th
|
83.3%
74th
|
| Capex / operating cash flow | 36.8%
52nd
|
19.7%
31st
|
16.7%
26th
|
| Accruals ratio | 0.5%
92nd
|
-10.9%
22nd
|
-5.2%
50th
|
| Sloan accruals ratio | -5.5%
33rd
|
-3.7%
38th
|
-0.2%
55th
|
| Earnings quality score (0-1) | 0.75
4th
|
0.75
4th
|
0.75
4th
|
Scores & forensic checks
15 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| IS score | 26
12th
|
81
98th
|
65
83rd
|
| IS profitability | 46
65th
|
83
98th
|
64
83rd
|
| IS growth | 23
7th
|
72
79th
|
33
12th
|
| IS value | 57
83rd
|
32
30th
|
36
37th
|
| IS momentum | 44
5th
|
94
95th
|
64
39th
|
| IS risk (safety) | 30
23rd
|
100
62nd
|
100
62nd
|
| IS quality | 61
58th
|
91
98th
|
82
85th
|
| IS balance sheet | 48
43rd
|
86
80th
|
94
98th
|
| IS earnings quality | 70
68th
|
53
37th
|
75
82nd
|
| IS cash flow | 29
20th
|
90
100th
|
89
97th
|
| Piotroski F-score (0-9) | 5
35th
|
9
95th
|
6
47th
|
| Altman Z-score | 1.7
28th
|
6.5
70th
|
12.7
88th
|
| Beneish M-score | −2.53
66th
|
−3.13
14th
|
−2.66
52nd
|
| Ohlson O-score | −7.02
52nd
|
−8.62
30th
|
−10.85
8th
|
| IS credit score | 49
35th
|
95
93rd
|
93
88th
|
Size (TTM)
8 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| Market cap | $31.4B
90th
|
$32.5B
92nd
|
$49.9B
93rd
|
| Revenue | $20.2B
93rd
|
$5.0B
87th
|
$6.5B
88th
|
| EBITDA | $3.5B
93rd
|
$1.6B
87th
|
$1.6B
88th
|
| Net income | $1.6B
93rd
|
$999.7M
88th
|
$1.0B
90th
|
| Free cash flow | $895.0M
87th
|
$1.4B
88th
|
$1.4B
90th
|
| Total assets | $37.2B
93rd
|
$6.5B
83rd
|
$13.9B
90th
|
| Shareholders' equity | $11.0B
92nd
|
$2.6B
80th
|
$10.6B
90th
|
| Employees | 54,000
93rd
|
11,050
82nd
|
16,000
87th
|
Price performance
9 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| 1 day | −1.1% | −1.9% | −1.7% |
| 1 week | +5.8% | +2.3% | +1.6% |
| 1 month | +8.0% | −2.1% | −1.9% |
| 3 months | +10.8% | +13.7% | +1.9% |
| 6 months | −6.8% | +34.5% | +6.9% |
| Year to date | −16.0% | +29.3% | +1.5% |
| 1 year | −5.0% | +31.5% | +18.7% |
| 3 years, cumulative | +3.0% | +8.9% | +21.7% |
| 5 years, cumulative | — | −35.0% | −20.4% |
Technicals
4 measures| Measure | GEHC | DXCM | EW |
|---|---|---|---|
| RSI 14 | 61.0 | 50.3 | 49.2 |
| From 52-week high | −22.5% | −7.1% | −10.1% |
| From 52-week low | +18.4% | +59.0% | +19.6% |
| Beta | 0.85 | 1.48 | 0.86 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17